



February 16, 2022

BSE Limited

Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

National Stock Exchange of India Limited

Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 051

Dear Sirs,

In terms of Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a copy of Press Release being issued by the Company on the following subject:

‘Jubilant Ingrevia Limited Commissions new facility for Diketenes & Derivatives.’

We request you to take the same on records.

Thanking you,

Yours faithfully,
For Jubilant Ingrevia Limited

Deepanjali Gulati
Company Secretary

Encl.: as above

A Jubilant Bhartia Company

OUR VALUES



Jubilant Ingrevia Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantingrevia.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
Uttar Pradesh, India
CIN : L24299UP2019PLC122657



Jubilant Ingrevia Limited
1A, Sector 16A, Noida – 201301, India
Tel.: +91 120 4361000
www.jubilantingrevia.com

JUBILANT INGREVIA LIMITED COMMISSIONS NEW FACILITY FOR DIKETENES & DERIVATIVES

DEMONSTRATES COMMITMENT TO CONTINUED GROWTH FROM ADVANCED, HIGH- POTENTIAL CHEMISTRY PLATFORMS

Noida, UP, India, February 16, 2022: Jubilant Ingrevia Limited, a global integrated Life Science products and Innovative Solutions provider with over 42 years of experience offering over 165 products & innovative solutions using more than 35 key chemistry and technology platforms across its three portfolio of businesses viz Acetyls, Pyridines and Vitamins & Premixes, today announced the commissioning of its new Diketene derivatives facility at its manufacturing site in North India at Gajraula, Uttar Pradesh.

Jubilant Ingrevia Limited for many years has niche expertise in using Ketene chemistry technology. Using the Ketene chemistry capability, the Company has developed a range of Diketene Derivatives. The newly commissioned facility marks the entry of Jubilant Ingrevia Limited into the fast growing Diketene business portfolio. This reiterates Jubilant Ingrevia Limited's commitment towards growth through its integrated business model, by providing value added products & innovative solutions to its customers.

The commissioned facility has about 7,000 TPA capacity to produce various Esters (Mono Methyl Acetoacetamide, Methyl Acetoacetate, Ethyl Acetoacetate and Ter-Butyl Acetoacetate). The Company's long-standing association with leading customers in Pharmaceuticals, Agrochemicals and other industries and its advance efforts to get product approval from customers, will help in utilizing a major portion of the capacity of this new facility in the coming months. Jubilant Ingrevia Limited undertakes to commission future phases of Diketene Derivatives as per plan.

On this occasion, Mr. Rajesh Srivastava, Chief Executive Officer and Managing Director, Jubilant Ingrevia Limited said,

"It gives me immense pleasure to showcase yet another instance where Jubilant Ingrevia Limited has developed a strong chemistry platform proposition using inhouse R&D and technology transfer backed with high operating excellence and clear strategic direction. The commercial launch of the Diketene facility marks the next stage in the growth of the Company, positioning us closer to our client's requirements of innovative products and solutions using novel and niche chemistry platform."

About Jubilant Ingrevia Limited

Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.

The Company offers a broad portfolio of high quality ingredients that find application in a wide range of industries. The company has 2,100 employees and serves more than 1,400 customers in more than 50 countries across the world. The Company's portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis.

Jubilant Ingrevia is a Responsible Care certified company, driven by the motive to add value to millions of lives through innovations and cutting-edge technology. As a leader in key products that the Company manufactures, it takes pride in being a partner of choice for its valued customers. For more information, please visit: www.jubilantingrevia.com.

For more information please contact:

For Investors:

Pavleen Taneja

Jubilant Ingrevia Limited

Ph: +91-120 436 1000

E-mail: pavleen.taneja@jubl.com

Siddharth Rangnekar / Karl H Kolah

CDR India

Ph: +91 97699 19966 / 98330 10478

E-mail: siddharth@cdr-india.com
karl@cdr-india.com

For Media & Press:

Sudhakar Safaya

Ph: +91 120 436 1062

E-mail: sudhakar.safaya@jubl.com

Clayton Dsouza

Madison Public Relations

Ph: +91 9930011602

E-mail: clayton.dsouza@madisonpr.in

Disclaimer: Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.
